@article{348b0ae6a149499aadc0180a8606843b,
title = "Increased liver decompensation risk with atypical hepatitis C virus antibody levels",
abstract = "Knowledge of serum markers of liver decompensation would facilitate care of patients with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections. HCV load and anti-c33c and anti-NS5 levels did not distinguish 28 HCV- and HIV-positive predecompensation patients from 28 matched control patients, whereas more patients than controls had high anti-c100(p) and low anti-c22(p). In multivariate analysis, decompensation was associated with high anti-c100(p) titer (≥1:4050; odds ratio [OR], 3.4; 95% confidence interval [CI], 1.1-11.5) and low anti-c22(p) (<1:36,450; OR, 3.0; 95% CI, 1.0-10.2) and with antibody band strength at 1:50 dilution (anti-c100[p] OR, 7.0; 95% CI, 1.7-48.9; anti-c22[p] OR, 7.1; 95% CI, 1.7-49.2). With high anti-c100(p) or low anti-c22(p), sensitivity for decompensation was 86%-96% and specificity was 21%-36%; with both markers, sensitivity was 29%-32% and specificity was 93%-96%. Although the mechanisms for these associations are unknown, if these findings are verified in other populations, anti-c100(p) and anti-c22(p) might be valuable surrogate markers for liver decompensation risk.",
author = "{Multicenter Hemophilia Cohort Study} and Goedert, {J. J.} and A. Hatzakis and Maloney, {E. M.} and Eyster, {M. E.} and Goedert, {J. J.} and O{\textquoteright}Brien, {T. R.} and Rosenberg, {P. S.} and Rabkin, {C. S.} and Engels, {E. A.} and M. Hisada and E. Maloney and Gail, {M. H.} and O{\textquoteright}Brien, {S. J.} and M. Dean and M. Carrington and M. Smith and C. Winkler and B. Konkle and M. Manco-Johnson and {Di Michele}, D. and Hilgartner, {M. W.} and P. Blatt and Aledort, {L. M.} and S. Seremetes and K. Hoots and Angiolillo, {A. L.} and Luban, {N. L.C.} and A. Cohen and Manno, {C. S.} and C. Leissinger and White, {G. C.} and Lederman, {M. M.} and S. Purvis and J. Salkowitz and Kessler, {C. M.} and A. Karafoulidou and T. Mandalaki and A. Hatzakis and G. Touloumi and W. Schramm and F. Rommel and {de Moerloose}, P. and S. Eichinger and Sherman, {K. E.} and D. Whitby and D. Waters and V. Lamprecht and Kroner, {B. L.}",
note = "Funding Information: Received 9 February 2000; revised 28 April 2000; electronically published 21 July 2000. Presented in part: 10th International Symposium on Viral Hepatitis and Liver Disease, Atlanta, April 2000 (abstract C109). Informed consent was obtained from the patients or their parents or guardians, and human experimentation guidelines of the US Department of Health and Human Services and those of the authors{\textquoteright} institutions were followed in the conduct of clinical research. Financial support: National Cancer Institute contract NO1-CP-33002 with Research Triangle Institute. a Institutions and investigators in the Multicenter Hemophilia Cohort Study are listed following the text. Reprints or correspondence: Dr. James J. Goedert, 6120 Executive Blvd., Ste. 8012, MSC 7248, Rockville, MD 20852 (
[email protected]).",
year = "2000",
month = jan,
day = "1",
doi = "10.1086/315712",
language = "English",
volume = "182",
pages = "590--594",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",
}